P. Duda

发表

Structure-function analysis of purified Enterococcus hirae CopB copper ATPase: effect of Menkes/Wilson disease mutation homologues.

K. Bissig, M. Solioz, H. Wunderli-Ye, 2001, The Biochemical journal.

Structure-function analysis of purified Enterococcus hirae CopB copper ATPase: effect of Menkes/Wilson disease mutation homologues.

K. Bissig, M. Solioz, H. Wunderli-Ye, 2001 .

A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes

D. Clifford, R. Zivadinov, B. Brew, 2013, Journal of Neurovirology.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

L. Kappos, C. Polman, F. Lublin, 2014, Neurology.

In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis.

J. Krieger, D. Hafler, M. Schmied, 2003, Clinical immunology.

Human and Murine CD4 T Cell Reactivity to a Complex Antigen: Recognition of the Synthetic Random Polypeptide Glatiramer Acetate1

J. Krieger, D. Hafler, M. Schmied, 2000, The Journal of Immunology.

This information is current as Acetate Synthetic Random Polypeptide Glatiramer a Complex Antigen : Recognition of the Human and Murine CD 4 T Cell Reactivity to

J. Krieger, D. Hafler, M. Schmied, 2000 .

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis

H. Wiendl, N. Gilhus, J. Vissing, 2021, Expert opinion on investigational drugs.

Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History

J. Mendell, T. B. Kinane, L. Lowes, 2017, Journal of neuromuscular diseases.

Portal Hypertension Promotes Bacterial Translocation in Rats Mono-and Non Mono-Associated with Escherichia Coli C 25 JEAN-NICOLAS VAUTHEY

Anthony, M., P. Gertsch, 2014 .

Portal Hypertension Promotes Bacterial Translocation in Rats Mono- and Non Mono-Associated with Escherichia Coli C25

J. Vauthey, P. Gertsch, A. M. Wheatley, 1994, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

J. Krieger, D. Hafler, M. Schmied, 2000, The Journal of clinical investigation.

MS disease activity in RESTORE

X. Montalban, L. Kappos, H. Hartung, 2014, Neurology.

Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis

M. Sweetser, H. Rossman, F. Forrestal, 2014, Journal of the Neurological Sciences.

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

M. Benatar, M. Bromberg, M. Pasnoor, 2020, JAMA neurology.

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE

X. Montalban, L. Kappos, H. Hartung, 2015, Journal of Neurology.

Experimental atrophy/hypertrophy complex (AHC) of the liver: portal vein, but not bile duct obstruction, is the main driving force for the development of AHC in the rat.

L. Blumgart, A. Zimmermann, P. Duda, 1995, Journal of hepatology.

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

L. Kappos, C. Scagnolari, G. Antonelli, 2007, Journal of Neurology.

The Janus face of CNS-directed autoimmune response: a therapeutic challenge.

L. Kappos, P. Duda, 2002, Brain : a journal of neurology.

Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis

C. Pozzilli, C. Polman, P. Sørensen, 2010 .

Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis

C. Pozzilli, C. Polman, R. Hohlfeld, 2005, European journal of neurology.

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

R. Ransohoff, G. Giovannoni, R. Fox, 2009, Neurology.

Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes

L. Kappos, A. Steck, M. Pletz, 2003, Journal of Neuroimmunology.

A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes

D. Clifford, R. Zivadinov, B. Brew, 2013, Journal of NeuroVirology.

Towards a European Network for Multiple Sclerosis Trials (ENMST)

A. Thompson, X. Montalban, L. Kappos, 2003, Multiple sclerosis.

The Enterococcus hirae Copper ATPases

M. Solioz, P. Duda, D. Strausak, 1996 .

Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study

G. Cutter, I. Aban, G. Wolfe, 2020, Muscle & nerve.

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

Adam L. Comer, Robert G. Miller, S. Demeret, 2023, The Lancet Neurology.

Cross‐sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment

G. Cutter, I. Aban, H. Kaminski, 2019, Muscle & nerve.

One‐year follow‐up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry

I. Aban, P. Duda, Justin M Leach, 2022, Muscle & nerve.

Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.

A. Mammen, B. Boroojerdi, I. Pinal-Fernandez, 2023, The Lancet. Rheumatology.

RA101495, A Subcutaneously Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis (gMG): Phase 1 Results and Phase 2 Design (S31.006)

M. Benatar, J. Howard, A. Ricardo, 2018 .

Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

L. Kappos, M. Schluep, G. Libero, 2005, European journal of neurology.

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.

J. Szer, H. Schrezenmeier, P. Muus, 2023, Haematologica.

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Nanqun Zhu, A. Ricardo, Yalan Tang, 2023, Frontiers in immunology.